Trial Profile
Phase I trial of orally administered irinotecan (Oratecan) in patients with solid tumours in the US.
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Oct 2014
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Athenex; Hanmi Pharmaceutical
- 23 Oct 2014 New trial record